Anti-SIGLEC5 [1A5]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-SIGLEC5 [1A5]
• Alternate name: Sialic Acid Binding Ig Like Lectin 5; Obesity-Binding Protein 2; OB-Binding Protein 2; CD33 Antigen-Like 2; SIGLEC-5; CD33L2; OBBP2; Sialic Acid-Binding Immunoglobulin-Like Lectin 5; CD17 Antigen;
• Research fields: Cell biology;Immunology
• Clone: 1A5
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Reactivity: Human
• Host: Mouse
• Application: IHC ; ELISA ; FACS ; IHC ; IF ; IP ; Fn ; WB
• Description: The Siglecs are a family of membrane bound lectins (of the immunoglobulin superfamily) that bind sialic acid and mediate cell-cell interactions. Siglec5 (CD170) is a member of the recently-described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33- related siglecs, Siglec-5 contains two tyrosine based motifs in its cytoplasmic tails implicated in signalling functions. The antibody cross reacts with Siglec14.
• Immunogen: Siglec-5-Fc protein, containing entire extracellular region of siglec-5 fused with the Fc region of human IgG1
• Isotype: IgG1
• Myeloma used: Sp2/0-Ag14
• Recommended controls: Siglec5 transfected CHO cells. Apart from Siglec14 (Angata T et al. 2006 FASEB J. 20:1964-73. PMID: 17012248), non-cross-reactive with panel of other Siglec proteins, either expressed on CHO cells or as recombinant proteins.

Target Details

• Target: Siglec5
• Tissue cell line specificity: Siglec5 transfected CHO cells. Apart from Siglec14 (Angata T et al. 2006 FASEB J. 20:1964-73. PMID: 17012248), non-cross-reactive with panel of other Siglec proteins, either expressed on CHO cells or as recombinant proteins.
• Target background: The Siglecs are a family of membrane bound lectins (of the immunoglobulin superfamily) that bind sialic acid and mediate cell-cell interactions. Siglec5 (CD170) is a member of the recently-described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33- related siglecs, Siglec-5 contains two tyrosine based motifs in its cytoplasmic tails implicated in signalling functions. The antibody cross reacts with Siglec14.

Applications

• Application: IHC ; ELISA ; FACS ; IHC ; IF ; IP ; Fn ; WB

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: -80° C
• Shipping conditions: Dry ice

References

• Angata et al. 2006. FASEB J. 20(12):1964-73. PMID: 17012248.
• Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates.
• Nguyen et al. 2006. Proc Natl Acad Sci U S A. 103(20):7765-70. PMID: 16682635.
• Loss of Siglec expression on T lymphocytes during human evolution.
• Avril et al. 2005. J Biol Chem. 280(20):19843-51. PMID: 15769739.
• Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.
• Connolly et al. 2002. Br J Haematol. 119(1):221-38. PMID: 12358929
• Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions.
• Cornish et al. 1998. Blood. 92(6):2123-32. PMID: 9731071.
• Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33.